Full TechWatch Meeting Presentation Guide (1 hour)

Please review the information below before creating a presentation for your Full TechWatch meeting. The information will guide you to ensure a productive and interactive meeting with the BARDA/USG team. During your meeting, BARDA staff will engage in technical discussion during your presentation to provide technical input, seek clarification, or to ask questions. Strategic guidance on alignment with BARDA will be provided during the closeout/Q&A.

Timeline:

- **One week prior to your meeting** send your draft presentation to the TechWatch team to review.
  - Please refer to your Meeting Invitation email for TechWatch Team contact info.
- **At least 24-48 hours prior to your meeting:**
  - Send your final presentation as a PowerPoint or PDF file to the TechWatch team to allow USG colleagues time to review your slides in advance, AND
  - Upload your final presentation materials to the BDR Stakeholder Portal.
- **On the day of the meeting:** please arrive 5 minute early to the meeting for the initial meeting frame-in and to ensure an on time start.

General Guidance for Full TechWatch:

- The meeting will be 60 minutes in duration; 45 minutes max for presentation (includes technical discussion throughout) and 15 minutes for Q&A/closeout discussion.
- The presentation should be data-driven and should not exceed 40-45 slides
- Explain how your technology aligns with the requirements stated in a specific area of interest (AOI) in BARDA's BAA or EZ-BAA or other solicitation opportunity (i.e., RRPV)
- Review information on Technology Readiness Level to determine the stage of maturity of your development program.

Specific Slide Guidance Content	# of Slides
Company Overview	**1**
Key Personnel	**1**
Product Pipeline Overview	**1**
Animation (graphic rendering of MOA or equivalent) *If possible, of how your technology works (i.e., MOA)*	**1**
Alignment *Specific AOI for BARDA's BAA and/or EZ-BAA, RRPV, BioMaP + TRL*	**1**
Proof-of-Concept Data	**~12-14**
Product Differentiation/Value Proposition (think stoplight table to demonstrate how your technology will result in better ROI) *Comparison to competing technologies; ROI to BARDA/USG (i.e., table with rows as attributes, columns are technologies)*	**1**
Regulatory *FDA feedback on development plan, and regulatory strategy for approval/licensure/clearance*	**~1-2**
Gantt Chart *Regulatory, nonclinical, clinical plan, manufacturing timelines*	**1**
Clinical Data/Development Plan	**~8-10**
Manufacturing (*onshoring of end-to-end manufacturing in the U.S.*)	**~-1-2**
Intellectual Property (*freedom to operate/unencumbered access; patents)*	**1**
Funding Landscape *High level review of estimated funding required to complete the development program/establish the capability through FDA licensure/approval/clearance*	**1**
Proposed Business Plan *For commercial/USG success to ensure sustainability*	**1**
Key Questions for BARDA *3-4 key questions*	**1**
Contact Details *Name, phone number, email address, website for POC*	**1**

TechWatch Meeting Presentation Guidance

Please review the information below before creating your presentation.

General Information and Specific Details Related to your TechWatch Meeting and for Inclusion in your Slide Presentation

- Full TechWatch, 1hr: ~40 slides (~40 min for presentation/technical discussion and ~10-15 minutes for closeout/Q&A for strategic overlay/alignment with BARDA)
- TechWatch Light, 45 min: ~30 slides (~30 min for presentation/technical discussion and ~10 minutes for closeout/Q&A for strategic overlay/alignment with BARDA)
- TechWatch Light 30 min: ~20 slides (~20 min for presentation/technical discussion and ~10 minutes for closeout/Q&A for strategic overlay/alignment with BARDA)
- Provide overview of your company (location(s), how long in business, number of employees, etc.)
- Provide key personnel (i.e., head shots, titles, logos of the companies from previous experience, etc.)
- Product Pipeline slide should showcase what is in development for all company assets, regardless of whether in scope for the BARDA mission
- Provide a description of your technology, whether a product (MCM) in development, socializing a technology platform, or showcasing a capability (i.e., manufacturing) and how it will apply or be repurposed to address a threat/pathogen in scope for the BARDA mission; this could be as a color rendering/graphic of the mechanism of action (MOA) for your product, or animation (short video) for the workflow of your diagnostic kit or manufacturing operation, as examples
- Explain how your technology aligns with requirements stated in a specific area of interest in BARDA's BAA, EZ-BAA, RRPV Consortium, and/or BioMaP Consortium
- It is important to thoroughly read and understand the requirements for AOIs detailed in the BAA and EZ-BAA, and/or the Consortium's RPPs when submitting your TechWatch meeting request to make sure it is truly a match for your technology
- Provide the Technology Readiness Level (must have completed the entire level and all elements of the previous levels to rank at a certain level: i.e., TRL6)
- Provide data to show the effectiveness of your technology
- Demonstrate data relative to BARDA
- Product Differentiation/Value Proposition slide to demonstrate potential ROI (think table in stoplight format with your technology as left column with 3-4 competing technologies to the right, and rows are attributes for you)
- Indicate whether you have received any FDA feedback on your development plan
- Provide the regulatory strategy related to your technology and the FDA's approval, licensure, or clearance process
- Present a Gantt chart that details by quarter how long it will take to achieve approval/licensure/clearance for your product (regulatory, clinical development plan and manufacturing as separate timelines to completion)
- Present your clinical development plan, if applicable
- Manufacturing (do you have or have plans to establish an end-to-end manufacturing process within the U.S.; important once partnering with BARDA is established to onshore all elements for manufacturing)
- Intellectual Property (do you have freedom to operate; unencumbered access to develop, manufacture and sell/market the product in the U.S.)
- Funding landscape (30k foot level look at funding needed in round number estimates to take your development program from the current point to completion (i.e., FDA licensure for a vaccine candidate)
- Business Plan (how you intend to be competitive in the commercial market (and/or with USG procurement where applicable) to ensure you have a viable, successful company; this ensures sustainability to derisk a USG investment)
- List the questions you would like answered by BARDA's staff, centered on whether your technology is aligned to the requirements for the specific BARDA opportunity (possibly multiple matches) and competitive to other related technologies that might be of interest of BARDA to also evaluate
- As the final slide, please include contact information (name, title, phone number, email address and website if established) as POC for any follow up directly from BARDA or USG colleagues (we only invite USG colleagues through their USG email addresses to protect confidentiality, which we are bound to uphold by federal law)